Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Veru Inc. has announced clinical data from the discontinued Phase 3 ARTEST clinical trial of enobosarm monotherapy for metastatic breast cancer. The trial was discontinued to prioritize and focus the clinical development of enobosarm therapy earlier in the treatment sequence. The data reported may not be predictive of the results of larger, later-stage controlled clinical trials.
September 11, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Veru Inc. has discontinued a Phase 3 trial to focus on the development of enobosarm therapy earlier in the treatment sequence. The reported data may not predict the results of future trials.
The discontinuation of the trial indicates a shift in Veru's strategy towards earlier treatment sequences. However, the reported data's lack of predictability for future trials introduces uncertainty, which could impact investor sentiment and the stock's short-term performance.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100